Aliases & Classifications for Substance Abuse

MalaCards integrated aliases for Substance Abuse:

Name: Substance Abuse 12 29 15
Substance-Related Disorders 43 71
Substance Abuse Problem 71


External Ids:

Disease Ontology 12 DOID:302
MeSH 43 D019966
NCIt 49 C16522
SNOMED-CT 67 26416006
UMLS 71 C0013146 C0236969 C0740858

Summaries for Substance Abuse

Disease Ontology : 12 A substance-related disorder that involves a maladaptive pattern of substance use leading to significant impairment in functioning.

MalaCards based summary : Substance Abuse, also known as substance-related disorders, is related to depression and cannabis abuse, and has symptoms including symptoms An important gene associated with Substance Abuse is MIAT (Myocardial Infarction Associated Transcript), and among its related pathways/superpathways are Peptide ligand-binding receptors and Transmission across Chemical Synapses. The drugs Acetylcholine and Ritonavir have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and liver, and related phenotypes are behavior/neurological and endocrine/exocrine gland

Wikipedia : 74 Substance abuse, also known as drug abuse, is use of a drug in amounts or by methods which are harmful... more...

Related Diseases for Substance Abuse

Diseases in the Substance Abuse family:

T-Substance Anomaly

Diseases related to Substance Abuse via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 365)
# Related Disease Score Top Affiliating Genes
1 depression 33.6 SLC6A4 MAOA BDNF
2 cannabis abuse 33.4 GABRA2 DRD4 DRD2 COMT BDNF
3 opioid abuse 33.4 DRD5 DRD3 DRD2 CYP2D6
4 amphetamine abuse 33.3 SLC6A4 SLC6A3 HTR1B DRD5 DRD4
5 alcohol use disorder 33.3 SLC6A4 SLC6A3 HTR1B GABRA2 DRD3 DRD2
6 eating disorder 33.3 SLC6A4 SLC6A3 NPY DRD3 DRD2 COMT
7 schizoaffective disorder 33.2 SLC6A4 PRL DRD4 DRD3 DRD2 COMT
8 borderline personality disorder 33.2 SLC6A4 SLC6A3 PRL MAOA HTR1B DRD2
9 cocaine abuse 33.1 SLC6A4 SLC6A3 PRL MOBP DRD3 DRD2
10 bipolar disorder 32.9 SLC6A4 SLC6A3 PRL MAOA HTR1B GABRA2
11 schizophrenia 32.3 SLC6A4 SLC6A3 PRL NPY MOBP MIAT
12 personality disorder 31.9 SLC6A4 SLC6A3 PRL MAOA HTR1B DRD4
13 drug dependence 31.9 SLC6A4 SLC6A3 NPY GABRA2 DRD3 DRD2
14 avoidant personality disorder 31.9 SLC6A4 SLC6A3 MAOA HTR1B DRD4 DRD3
15 brain injury 31.8 DRD2 COMT BDNF
16 disease of mental health 31.8 SLC6A4 SLC6A3 NPY MAOA DRD5 DRD4
17 traumatic brain injury 31.8 DRD2 COMT BDNF
18 opiate dependence 31.8 SLC6A4 SLC6A3 DRD4 DRD3 DRD2
19 alcohol dependence 31.8 SLC6A4 SLC6A3 PRL NPY MAOA HTR1B
20 conduct disorder 31.7 SLC6A4 SLC6A3 MAOA GABRA2 DRD5 DRD4
21 substance dependence 31.6 SLC6A4 SLC6A3 MAOA HTR1B GABRA2 DRD5
22 polysubstance abuse 31.6 DRD3 DRD2 COMT
23 antisocial personality disorder 31.6 SLC6A4 SLC6A3 PRL MAOA HTR1B GABRA2
24 post-traumatic stress disorder 31.6 SLC6A4 NPY MAOA DRD2 DBH COMT
25 mental depression 31.5 SLC6A4 SLC6A3 MAOA HTR1B DRD4 DRD2
26 mood disorder 31.5 SLC6A4 SLC6A3 NPY MAOA HTR1B DRD4
27 alexithymia 31.4 SLC6A4 DRD2 COMT
28 tobacco addiction 31.4 SLC6A4 SLC6A3 MAOA GABRA2 DRD5 DRD4
29 cocaine dependence 31.4 SLC6A4 SLC6A3 PRL HTR1B GABRA2 DRD3
30 anxiety 31.4 SLC6A4 SLC6A3 PRL NPY MAOA HTR1B
31 adjustment disorder 31.3 SLC6A4 NPY BDNF
32 pathological gambling 31.3 SLC6A4 SLC6A3 MAOA DRD5 DRD4 DRD3
33 dysthymic disorder 31.3 SLC6A4 MAOA BDNF
34 social phobia 31.3 SLC6A4 PRL MAOA DRD2 COMT
35 agoraphobia 31.2 SLC6A4 MAOA COMT
36 psychotic disorder 31.2 SLC6A4 SLC6A3 PRL MAOA DRD5 DRD4
37 anorexia nervosa 31.2 SLC6A4 PRL NPY MAOA DRD4 COMT
38 sleep disorder 31.2 SLC6A4 SLC6A3 PRL DRD2 BDNF
39 attention deficit-hyperactivity disorder 31.2 SLC6A4 SLC6A3 PRL NPY MAOA HTR1B
40 generalized anxiety disorder 31.2 SLC6A4 SLC6A3 NPY MAOA DRD2 CYP2D6
41 bipolar i disorder 31.1 SLC6A4 DRD4 DRD3 DRD2 COMT BDNF
42 postpartum depression 31.1 SLC6A4 PRL MAOA COMT BDNF
43 opioid addiction 31.1 DRD2 COMT
44 oppositional defiant disorder 31.1 SLC6A4 SLC6A3 MAOA DRD4 DRD2 DBH
45 sexual disorder 31.1 SLC6A4 PRL DRD2 CYP2D6
46 amnestic disorder 31.0 DRD2 BDNF BCHE
47 major depressive disorder 31.0 SLC6A4 SLC6A3 PRL NPY MAOA HTR1B
48 tardive dyskinesia 31.0 DRD3 DRD2 CYP2D6 COMT
49 bulimia nervosa 31.0 SLC6A4 PRL NPY MAOA HTR1B DRD4
50 neurotic disorder 31.0 SLC6A4 MAOA BDNF

Graphical network of the top 20 diseases related to Substance Abuse:

Diseases related to Substance Abuse

Symptoms & Phenotypes for Substance Abuse

UMLS symptoms related to Substance Abuse:


MGI Mouse Phenotypes related to Substance Abuse:

# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.16 BDNF COMT CYBB DBH DRD2 DRD3
2 endocrine/exocrine gland MP:0005379 9.81 BDNF COMT DBH DRD2 DRD5 HTR1B
3 homeostasis/metabolism MP:0005376 9.8 BCHE BDNF COMT CYBB DBH DRD2
4 nervous system MP:0003631 9.5 BDNF COMT CYBB DBH DRD2 DRD3

Drugs & Therapeutics for Substance Abuse

Drugs for Substance Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 494)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
Nicotine Approved Phase 4 54-11-5 942 89594
Lithium carbonate Approved Phase 4 554-13-2
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
Desipramine Approved, Investigational Phase 4 50-47-5 2995
Memantine Approved, Investigational Phase 4 19982-08-2 4054
Clonidine Approved Phase 4 4205-90-7 2803
Baclofen Approved Phase 4 1134-47-0 2284
Amantadine Approved Phase 4 768-94-5 2130
Mirtazapine Approved Phase 4 85650-52-8, 61337-67-5 4205
Histamine Approved, Investigational Phase 4 51-45-6 774
Acetaminophen Approved Phase 4 103-90-2 1983
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
Ziprasidone Approved Phase 4 146939-27-7 60854
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
Chlorpromazine Approved, Investigational, Vet_approved Phase 4 50-53-3 2726
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
Amphetamine Approved, Illicit, Investigational Phase 4 300-62-9 5826 3007
Dextroamphetamine Approved, Illicit Phase 4 51-64-9 5826
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
Dronabinol Approved, Illicit Phase 4 1972-08-3 16078
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
Carbon monoxide Approved, Investigational Phase 4 630-08-0 281
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
Brexpiprazole Approved, Investigational Phase 4 913611-97-9 11978813
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
Cobicistat Approved Phase 4 1004316-88-4
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
Rifapentine Approved, Investigational Phase 4 61379-65-5 6323497
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
Levonorgestrel Approved, Investigational Phase 4 797-63-7, 17489-40-6 13109
Desogestrel Approved Phase 4 54024-22-5 40973
Etonogestrel Approved, Investigational Phase 4 54048-10-1 40976 6917715
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
Cocaine Approved, Illicit Phase 4 50-36-2 5760 446220
Methadone Approved Phase 4 76-99-3 4095
Clozapine Approved Phase 4 5786-21-0 2818
Morphine Approved, Investigational Phase 4 57-27-2 5288826
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603

Interventional clinical trials:

(showing 2010, show less)
# Name Status NCT ID Phase Drugs
1 Cognitive Correlates of Substance Abuse, Part 1 Unknown status NCT00000346 Phase 4
2 Smoking Cessation Treatment for Methadone Maintenance Patients Unknown status NCT01027754 Phase 4 Varenicline;Placebo
3 An Evaluation of Innovative Methods for Integrating Buprenorphine Opioid Treatment in HIV Primary Care Settings Unknown status NCT00124358 Phase 4 Buprenorphine
4 Association Between Motorcycle Accidents, Attention Deficit/Hyperactivity Disorder and Substance Use Disorder and Motorcycle Accidents Unknown status NCT00536419 Phase 4 Methylphenidate
5 Study of Associated Gene Polymorphisms With Atomoxetine Response Prediction in ADHD Treatment Unknown status NCT01339286 Phase 4 atomoxetine
6 Aggressive Behaviour in Children With Tourette's Syndrome (TS) and Comorbid Attention Deficit Hyperactivity Disorder (ADHD) Unknown status NCT00152750 Phase 4 APO-clonidine
7 Three Strategies for Implementing Motivational Interviewing on Medical Inpatient Units: See One, Do One, Order One Unknown status NCT01825057 Phase 4
8 A Multi-Center,Open-Labeled,Intervention Study:The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation Unknown status NCT02935998 Phase 4 Ziprasidone
9 A Controlled Study of the Efficacy of Botulinum Toxin A (Botox) for the Treatment of Major Depressive Disorder (MDD) Unknown status NCT01556971 Phase 4 Botox;Saline Solution
10 An Open-label, Randomised Pilot Study Comparing the Efficacy, Safety and Tolerability of Raltegravir With Protease Inhibitor-based Therapy in Treatment-naïve, HIV/Hepatitis C Co-infected Injecting Drug Users Receiving Methadone Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir
11 Depakote ER Therapy for Mania Comorbid With Substance Abuse Completed NCT00208195 Phase 4 Divalproex ER
12 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
13 The Impact of Quetiapine on the Drug Abuse Patterns of Addicted Schizophrenic Patients Completed NCT00295412 Phase 4 quetiapine (drug)
14 Pilot Study of Vyvanse™ (Lisdexamfetamine Dimesylate) in Adolescents (Ages 11-15) With ADHD and an Older Sibling With ADHD and Substance Dependence Completed NCT00573534 Phase 4 Vyvanse
15 Aripiprazole (Abilify) Therapy for Reducing Comorbid Substance Abuse Completed NCT00208169 Phase 4 Aripiprazole
16 Relapse Prevention With Varenicline Completed NCT00944554 Phase 4 Varenicline;Placebo
17 Translating Depression Guidelines Into Substance Abuse Treatment Completed NCT00137306 Phase 4
18 A Double-blind Placebo Controlled Trial of Pregnenolone for Depression in Patients With Bipolar Disorders or Recurrent Major Depressive Disorder and a History of Substance Abuse Completed NCT00223197 Phase 4 Pregnenolone
19 Buprenorphine to Improve HIV Care Engagement and Outcomes: A Randomized Trial (BRAVO) Completed NCT01936857 Phase 4 Buprenorphine/naloxone;Methadone Maintenance Therapy
20 On-Site Addiction Treatment With Buprenorphine in HIV Clinical Care Settings Completed NCT00317460 Phase 4
21 Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral Treatment Completed NCT00844272 Phase 4
22 Seroquel (Quetiapine) Therapy for Schizophrenia and Schizoaffective Disorders and Comorbid Cocaine and/or Amphetamine Abuse/Dependence: A Comparative Study With Risperidone Completed NCT00208143 Phase 4 Quetiapine;Risperidone
23 Divalproex ER vs. Risperidone for Bipolar Disorder With Comorbid Substance Use Disorder Completed NCT00203528 Phase 4 divalproex sodium ER;risperidone
24 Atomoxetine in Adolescents With Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorder (SUD) Completed NCT00218322 Phase 4 Atomoxetine hydrochloride;Placebo
25 Improving Hepatitis C Treatment in Injection Drug Users Completed NCT00148031 Phase 4 Pegylated Interferon and Ribavirin
26 Methamphetamine Abuse Pharmacology in Patients With AIDS Completed NCT00000321 Phase 4 Desipramine
27 Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence Completed NCT00330239 Phase 4 Paroxetine CR
28 Prevention Services in Schools for Early Drug Abuse Risk Completed NCT00257088 Phase 4
29 Efficacy of Quetiapine in the Reduction of Cocaine Use and Cravings in Individuals With Cocaine Dependence Completed NCT00232336 Phase 4 quetiapine
30 Efficacy of Quetiapine in Treating Patients With Active Substance Use Disorder and Schizophrenia Completed NCT00156715 Phase 4 Quetiapine
31 Efficacy & Safety of Baclofen to Reduce Alcohol Use in Veterans With HCV Completed NCT01008280 Phase 4 baclofen;placebo
32 Bupropion for ADHD in Adolescents With Substance Use Disorder Completed NCT00936299 Phase 4 Bupropion
33 Brain Changes in Stimulant Dependent Subjects Completed NCT00000343 Phase 4
34 Pharmacotherapy and Intensive Treatment Completed NCT00000218 Phase 4 Carbamazepine
35 Methylphenidate Raclopride PET Test Completed NCT00015301 Phase 4 Methylphenidate
36 Pathophysiological Subtyping of Abnormalities in Cocaine Dependence Completed NCT00015275 Phase 4
37 Modeling Impaired Judgement in Cocaine Abusers Completed NCT00015236 Phase 4
38 A Prospective Cohort Study Comparing the Effectiveness of Zepatier for the Treatment of Hepatitis C in an Academic Center Population to People Who Inject Drugs (PWIDs) in a Safety Net Clinic Setting Engaged in Either a Medication Assisted Therapy (MAT) or Syringe Exchange Program Completed NCT03093415 Phase 4 elbasvir-grazoprevir (50 mg/100 mg)
39 Effectiveness of Naltrexone in a Community Setting Completed NCT00000445 Phase 4 naltrexone (Revia)
40 Abuse Liability of Controlled-Release Oxycodone Formulations Completed NCT02101840 Phase 4 Apo-Oxycodone CR®;OxyNEO®;Placebo
41 Buprenorphine/Nx Treatment of Heroin Dependence-A Compassionate Use Study Completed NCT00015340 Phase 4 Buprenorphine/naloxone
42 Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia Completed NCT02396979 Phase 4 Methadone
43 A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects Completed NCT00605033 Phase 4 Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484;Subutex, Buprenorphine Hydrochloride, SCH 28444
44 The Effects of Intranasal Oxytocin on Social Cognition, Implicit Preferences and Craving in Moderate to Heavy Social Alcohol Drinkers Completed NCT01829516 Phase 4 Oxytocin;Placebo
45 Drug Contextual Conditioning With in Humans: Causes and Consequences Completed NCT03075501 Phase 4 Stimulant or sedative;Placebo
46 Substance Dependent Teens - Impact of Treating Depression Study 1 Completed NCT00061113 Phase 4 Fluoxetine + outpatient cognitive behavioral therapy;fluoxetine;placebo + CBT
47 Reinforcement-Based Treatment and Abstinence-Contingent Housing for Drug Abusers Completed NCT00685620 Phase 4
48 Treatment of Acute Hepatitis C Virus Infection in Injection Drug Users With Pegylated Interferon for 24 Weeks Completed NCT00194480 Phase 4 Pegylated Interferon
49 Vilazodone for Separation Anxiety Disorder Completed NCT01999920 Phase 4 Vilazodone;Placebo
50 Field Study of Smoking Cessation in Alcoholism Treatment Completed NCT00000454 Phase 4 nicotine replacement patch
51 Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist Completed NCT01673594 Phase 4 SODAS MPH;Naltrexone
52 A Multicentre, Randomised, Open-label, Active-controlled Trial of the Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France Completed NCT00955162 Phase 4 Buprenorphine (Subutex);Buprenorphine/naloxone (Suboxone)
53 VIVITROL® (Naltrexone for Extended Release Injectable Suspension (XR-NTX)) for Opioid Dependent Inmates Released From Prison Completed NCT01563718 Phase 4 naltrexone for extended release injectable suspension
54 Project STRIDE2 - Seek/Test/Retain: PLWHA and Opioid Users in Washington, DC Completed NCT03583138 Phase 4 buprenorphine
55 Health Services Research: Extended Release Naltrexone for Opioid-Dependent Youth Completed NCT01843023 Phase 4 Extended Release Naltrexone;Buprenorphine
56 Intensive Outpatient v. Outpatient Treatment With Buprenorphine Among African Americans Completed NCT01096550 Phase 4
57 Treatment of Polydrug-Using Opiate Dependents During Withdrawal Completed NCT00367874 Phase 4 Buprenorphine;Valproate
58 Evaluation of Preference for a Buprenorphine-based Maintenance Therapy, After a Switch From Buprenorphine Alone (Subutex®) to the Buprenorphine/Naloxone Combination (Suboxone®), in Opioid-dependent Patients With Buprenorphine Maintenance Therapy Completed NCT00684073 Phase 4 buprenorphine;buprenorphine/naloxone
59 Cannabis and Schizophrenia: Effects of Clozapine Completed NCT00498550 Phase 4 Clozapine;Treatment as usual
60 Integrating Buprenorphine Into the SFGH AIDS Program (Patient Evaluation Study) Completed NCT00263458 Phase 4
61 Attention Training for Opioid-maintained Cocaine Users Completed NCT01870882 Phase 4
62 Multimodal Treatment Study of Children With ADHD Completed NCT00000388 Phase 4 Anti-ADHD medication
63 Relapse Prevention to Reduce HIV Among Women Prisoners Completed NCT00763958 Phase 4 Placebo;Buprenorphine
64 Perioperative Administration of Pregabalin in Patients Undergoing Arthroscopic Anterior Cruciate Ligament Reconstruction: Does it Help to Relieve Postoperative Pain? Completed NCT01242332 Phase 4 Pregabalin
65 Genetic and Brain Mechanisms of Naltrexone?s Treatment Efficacy for Alcoholism Completed NCT00920829 Phase 4 Naltrexone 50 Mg;Placebo
66 Risperidone Long-Acting for Alcohol and Schizophrenia Treatment (R-LAST) Completed NCT00130923 Phase 4 Risperidone Long Acting;oral risperidone
67 Creatine as a Treatment Option for Depression in Methamphetamine Using Females Completed NCT01514630 Phase 4 Creatine monohydrate
68 Adolescent Family-Based Alcohol Prevention Completed NCT00858065 Phase 4
69 An Integrated Approach With Vardenafil Orodispersible and Cognitive-behavioral Sex Therapy for the Treatment of Erectile Dysfunction (STEDOV) Completed NCT02450188 Phase 4 Vardenafil
70 Control of Cognition: Naltrexone, Methylphenidate, and ADHD Study Completed NCT01993108 Phase 4 Methylphenidate;Naltrexone;Placebo
71 A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial of Citicoline as an add-on Therapy Will be Conducted in 200 Outpatients With Bipolar I Disorder and Cocaine Dependence. Completed NCT00619723 Phase 4 Citicoline;Placebo
72 Progesterone Reduces Wakefulness in Sleep EEG and Has no Effect on Cognition in Healthy Postmenopausal Women Completed NCT00530582 Phase 4 progesterone
73 Naltrexone for Bipolar Disorder and Alcohol Dependence Completed NCT00223275 Phase 4 Naltrexone
74 Open-label Multicenter Study to Assess the Efficacy, the Tolerability and the Adherence of a Once Daily (QD) Taken Antiretroviral Therapy (ART) Containing the NtRTI Tenofovir DF 300 mg in Combination With the Best Suitable Once a Day Regimen Being 1 NRTI Plus 1 PI or 1 NRTI Plus 1 NNRTI in HIV-1-infected IVDU- Patients With Opiate Substitution Being Either Antiretroviral-naive or With Suppressed Viral Load and Without a History of Virological Failure Completed NCT00324688 Phase 4 Viread
75 Attenuation of Corticosteroid Induced Hippocampal Changes Completed NCT01656187 Phase 4 Memantine 10 mg capsule;Memantine-matched Placebo capsule
76 A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users Completed NCT00604188 Phase 4 Suboxone (SCH 000484);Subutex (SCH 028444)
77 Comparing Opioid Prescription Patterns in Total Joint Arthroplasty Patients: A Randomized Controlled Trial Completed NCT03236155 Phase 4 opioid pain pills
78 Abstinence Reinforcement Therapy (ART) for Homeless Veteran Smokers Completed NCT02245308 Phase 4 Nicotine Patches;Nicotine rescue method;Bupropion
79 Stimulant and Risperidone in Children With Severe Physical Aggression Completed NCT00796302 Phase 4 Methylphenidate HCl;Risperidone;Placebo
80 A Placebo-Controlled Study of Mirtazapine for PTSD in OIF/OEF Veterans Completed NCT00302107 Phase 4 Mirtazapine;Placebo
81 Prophylactic Mirtazapine or Clonidine for Post-spinal Anesthesia Shivering in Patients Undergoing Urological Surgeries: a Randomized Controlled Trial Completed NCT03679052 Phase 4 Mirtazapine;Clonidine;Placebo
82 Prophylactic Mirtazapine or Dexamethasone for Post-spinal Anesthesia Shivering in Patients Undergoing Gynecological Surgeries: a Randomized Controlled Trial Completed NCT03675555 Phase 4 Mirtazapine;Dexamethasone phosphate;Placebo
83 SWITCH OR ADD PEGYLATED-INTERFERON IN CHRONIC HEPATITIS B PATIENTS ON LONG TERM NUCLEOS(T)IDE THERAPY (SWAP TRIAL) Completed NCT01928511 Phase 4 peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly;Nucleos(t)ide analogue therapy
84 Prophylactic Paracetamol or Dexamethasone for Post-spinal Anesthesia Shivering in Patients Undergoing Non-obstetric Surgeries: a Randomized Controlled Trial Completed NCT03679065 Phase 4 Paracetamol;Dexamethasone;Placebo
85 A Comparison of Bupropion SR and Placebo for Smoking Cessation Completed NCT00176449 Phase 4 Bupropion SR;Placebo Oral Tablet
86 Risperidone Augmentation for Treatment-Resistant Aggression in ADHD Completed NCT00297739 Phase 4 Risperidone
87 A Placebo-Controlled, Cross-Over Trial of Aripiprazole Added to Obese Olanzapine-Treated Patients With Schizophrenia Completed NCT00351936 Phase 4 Aripiprazole;placebo
88 An Open Label Trial of Ziprasidone as an Adjuvant for Clozapine- or Olanzapine-Associated Diabetes Mellitus or Impaired Fasting Glucose in Chronic Schizophrenia Completed NCT00351000 Phase 4 Ziprasidone
89 Randomized Clinical Trial Comparing a Medication, i.e., Sustained-Release Bupropion (Zyban®) With an Ultrashort (1 1/2 d) Manual-Based Psychotherapeutic Intervention, Psychodynamic Model Training® Completed NCT00484692 Phase 4 sustained-release bupropion (Zyban(R))
90 Comparison of Combination Olanzapine and Lithium and Combination Chlorpromazine and Lithium in the Treatment of a First Manic Episode With Psychotic Features. Completed NCT00202293 Phase 4 Olanzapine;Lithium;Chlorpromazine
91 A Randomized, Open-label, Comparative Study to Evaluate an Intermittent Dosing Regimen of Fluticasone Propionate 0.05% Cream (Twice Per Week) in Reducing the Risk of Relapse When Added to Regular Daily Moisturization Using PHYSIOGEL Lotion in Paediatric Subjects With Stabilized Atopic Dermatitis Completed NCT01915914 Phase 4 Fluticasone propionate
92 Sitagliptin Dose Determination Study in Type 1 Diabetes Completed NCT01530178 Phase 4 Sitagliptin;Placebo Oral Tablet
93 Randomized, Double-blind, Placebo-controlled Trial to Measure the Efficacy and Safety of Vitamin D3 in Patients With Fibromyalgia. Completed NCT03369379 Phase 4 D3 Vitamin
94 Antidepressant Treatment at an Inner City Asthma Clinic Completed NCT01324700 Phase 4 High severity group: Escitalopram;High severity group: Placebo;Low severity group: Escitalopram;Low severity group: Placebo
95 Brain Indices of Stimulant Treatment in Drug-Naive Youth at Risk for Substance Use Disorder Recruiting NCT04170738 Phase 4 Adderall
96 Management of Hepatitis C Virus (HCV) Infection in Pregnant Women With Opioid Use Disorder (OUD): the Potential of an Integrated Medical Home Model: Phase IV Trial of Sofosbuvir/Velpatasvir (SOF/VEL) in Postpartum Women With Chronic HCV Recruiting NCT03057847 Phase 4 Sofosbuvir/Velpatasvir
97 Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance During the Quantified Behavior Test in Patients With Untreated ADHD and Substance Use Disorder Recruiting NCT02477280 Phase 4 Methylphenidate;Placebo
98 A Randomized Controlled Trial of Quetiapine for the Treatment of Youth With Co-occurring Substance Use Disorders and Severe Mood Dysregulation Recruiting NCT02845453 Phase 4 Quetiapine;Placebo
99 A Multi-center, Randomized, Controlled Trial of Brexpiprazole for the Treatment of Co-occurring Schizophrenia and Substance Use Disorder Recruiting NCT03526354 Phase 4 Brexpiprazole
100 Comparison of Buprenorphine vs Buprenorphine/Naloxone on the Effects of Maternal Symptomatology Recruiting NCT03740243 Phase 4 Buprenorphine/naloxone;Buprenorphine
101 Feasibility and Acceptability of Digital Pills to Monitor PrEP Adherence in MSM With Substance Use Recruiting NCT03842436 Phase 4 Truvada
102 A Randomized Double-Blind Controlled Trial of Creatine in Female Methamphetamine Users Recruiting NCT02192931 Phase 4 Creatine monohydrate
103 Houston Emergency Opioid Engagement System (HEROES) Recruiting NCT03396276 Phase 4 Suboxone
104 Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk Recruiting NCT03781765 Phase 4 Methylphenidate;Atomoxetine
105 Intravenous Lidocaine for Perioperative and Postoperative Analgesia Recruiting NCT03921567 Phase 4 Lidocaine Hydrochloride;Lidocaine Hydrochloride and Ketamine;Placebo
106 A Cognitive Behavioral Therapy Group Intervention for Adolescents With Attention-Deficit / Hyperactivity Disorder Recruiting NCT02566824 Phase 4 Methylphenidate or amphetamine product
107 Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (ECF/TAF) Switch Followed by Sofosbuvir/Velpatasvir (SOF/VEL) Antiviral HCV Therapy in HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy Recruiting NCT03549312 Phase 4 Genvoya;Epclusa
108 Novel Interventions for Alcohol Dependent Frequent Emergency Department Users: Phase IV, Randomized, Open-label, Non-placebo-controlled Study of Extended-release Naltrexone and Care Management on Healthcare Use, Drinking, & Quality of Life Recruiting NCT02445339 Phase 4 XR-NTX+CM (Extended-Release Naltrexone plus Care Management)
109 Neuroplasticity Following Theta-Burst Stimulation in Cocaine Use Disorder Recruiting NCT02927236 Phase 4
110 CPT-SMART for Treatment of PTSD and Cigarette Smoking Recruiting NCT03978442 Phase 4 Bupropion
111 Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings Recruiting NCT03089983 Phase 4 Naltrexone;Methadone;Isoniazid;Rifapentine
112 Using Imaging to Assess Effects of THC on Brain Activity Recruiting NCT03655717 Phase 4 Dronabinol;Ethanol;Placebo Dronabinol;Placebo Ethanol
113 Rapid Initiation of Buprenorphine/Naloxone to Optimize MAT Utilization in Philadelphia Recruiting NCT03908437 Phase 4 buprenorphine/naloxone
114 People Who Inject Drugs; Longitudinal Staphylococcus Aureus Colonization Pattern and the Impact on Infection Frequency by Regular Showers With Chlorhexidine Active, not recruiting NCT03940729 Phase 4 Chlorhexidine Topical
115 Effectiveness of Prolonged Use of IUD/Implant for Contraception Active, not recruiting NCT02267616 Phase 4
116 Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry Active, not recruiting NCT01999946 Phase 4 Extended-Release Naltrexone
117 An Open-label, Treatment Extension Study for the Rapid Initiation of Extended-Release Buprenorphine Subcutaneous Injection (SUBLOCADE™) Enrolling by invitation NCT04060654 Phase 4 Sublocade
118 Clozapine Versus Olanzapine as Treatment for Comorbid Psychotic Disorder and Substance Use Disorder Not yet recruiting NCT03857581 Phase 4 Clozapine;Olanzapine
119 A Prospective, Randomized Trial of the Effect of Standard of Care Reduced Dose Versus Full Dose Buprenorphine/Naloxone in the Perioperative Period on Pain Control and Post Operative Opioid Use Disorder Symptoms Not yet recruiting NCT03266445 Phase 4 buprenorphine/naloxone
120 A Prospective, Randomized Trial of the Effect of Standard of Care Reduced Dose Versus Full Dose Buprenorphine/Naloxone in the Perioperative Period on Pain Control and Post-Operative Opioid Use Disorder Symptoms Not yet recruiting NCT04091009 Phase 4 Buprenorphine;Buprenorphine/naloxone
121 Alcoholism and Schizophrenia: Effects of Clozapine Terminated NCT00169026 Phase 4 Clozapine versus typical (conventional) and atypical antipsychotic medications
122 Evaluation of Pregabalin's Abuse Liability and Its Effects on Benzodiazepine Withdrawal Symptoms in Inpatients Undergoing Medically Assisted Benzodiazepine Withdrawal Terminated NCT02423018 Phase 4 Pregabalin;Placebo
123 A Randomized Controlled Trial Testing Buprenorphine as a Treatment in Opiate Dependent Pain Patients Terminated NCT00552578 Phase 4 buprenorphine/naloxone;buprenorphine/naloxone
124 Comparison of Quetiapine and Trazodone Treatment for Insomnia in Dually Diagnosed Veterans: an Open (e.g. Unblinded) Randomized Stay-Switch Pilot Trial Terminated NCT01662297 Phase 4 Quetiapine;Trazodone
125 A Randomized, Double-blind, Placebo-controlled, Clinical Trial of Structured Opioid Discontinuation Versus Continued Opioid Therapy in Suboptimal and Optimal Responders to High-dose Long-term Opioid Analgesic Therapy for Chronic Pain. Terminated NCT02741076 Phase 4 Structured discontinuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER);Continuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)
126 Pilot Study of Depot Naltrexone in Alcohol-Dependent, Homeless Veterans Terminated NCT01155869 Phase 4 Depot naltrexone;Oral Naltrexone
127 Oxytocin and Cognitive Behavioral Therapy in Drug Dependence Terminated NCT00975416 Phase 4 Intranasal Oxytocin;Placebo
128 Escitalopram in Bipolar Depression: a Placebo-controlled Study of Acute and Maintenance Treatment Terminated NCT00464191 Phase 4 escitalopram
129 A Double-blind, Parallel, Randomized, add-on Clinical Trial of Creatine Versus Placebo Added to Antidepressant Treatment of Patients With Major Depressive Episode. Terminated NCT00313417 Phase 4
130 Improving Outcomes in Psychosis Associated With Substance Use Using Aripiprazole Withdrawn NCT01155544 Phase 4
131 Efficacy of Atomoxetine for Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents and Young Adults With Substance Use Disorders (SUD) Withdrawn NCT01207622 Phase 4 Atomoxetine;Placebo
132 A Randomized Controlled Trial Comparing Buprenorphine/Naloxone With Naltrexone for Treatment in Opioid Dependent Adolescents and Young Adults Withdrawn NCT01015066 Phase 4 Buprenorphine/naloxone;Naltrexone
133 An Evaluation of Divalproex vs. Olanzapine for Alcohol Abuse Relapse Prevention in Patients With Bipolar Disorder Withdrawn NCT00221481 Phase 4 divalproex or olanzapine
134 Family and Group Therapies for Adolescent Alcohol Abuse Unknown status NCT00484367 Phase 2, Phase 3
135 Comparing Acute and Continuous Drug Abuse Treatment: A Randomized Clinical Trial Unknown status NCT01003496 Phase 3
136 Implementation of an Evidence Based PTSD Treatment in Public Sector Settings Unknown status NCT01488539 Phase 2, Phase 3
137 Mirtazapine as a Treatment for Co-Occurring Opioid and Amphetamine Type Stimulant Dependence (COATS) in Malaysia Unknown status NCT02541526 Phase 3 Mirtazapine;Placebo
138 Women's Treatment for Trauma and Substance Use Disorders Completed NCT00078156 Phase 3
139 Motivational Enhancement for Spanish Speaking Individuals Completed NCT00078169 Phase 3
140 Acupuncture and the Relaxation Response for Homeless Veterans With Substance Abuse Completed NCT00375102 Phase 2, Phase 3
141 Motivational Incentives for Enhanced Drug Abuse Recovery: Methadone Clinics Completed NCT00033020 Phase 3
142 A Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® Completed NCT02537574 Phase 3 NTX/BUP;NTX/PBO-B;PBO-N/PBO-B
143 Motivational Interviewing (MI) to Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse Completed NCT00032994 Phase 3
144 Motivational Enhancement Treatment (MET) to Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse Completed NCT00032981 Phase 3
145 Effects of Manualized Treatment in a Seamless System of Care: Handling Probation Completed NCT01372033 Phase 3
146 A Randomized, Double Blind Comparison of Lithium Monotherapy Versus Lithium Plus Divalproex for the Outpatient Management of Hypomania/Mania in Patients With Rapid Cycling Bipolar Disorder Comorbid With Substance Abuse/Dependence Completed NCT00194129 Phase 3 Lithium;Divalproex;Placebo
147 Smoking Cessation in Substance Abuse Treatment Patients: A Feasibility Study Completed NCT00408265 Phase 3
148 Women-Focused HIV Prevention in the Western Cape Completed NCT00729391 Phase 2, Phase 3
149 Reducing Barriers to Drug Abuse Treatment Services Completed NCT00273845 Phase 2, Phase 3
150 Brief Strategic Family Therapy for Adolescent Drug Abusers Completed NCT00095303 Phase 3
151 Multidisciplinary Approach to Reduce Injury and Substance Abuse Completed NCT01048359 Phase 3
152 Randomized Controlled Trial of Osmotic-Release Methylphenidate (OROS-MPH) for Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents With Substance Use Disorders (SUD) Completed NCT00264797 Phase 3 Methylphenidate (OROS-MPH);Methylphenidate (OROS-MPH) - Placebo
153 Linkage of Alcohol Abusers to Primary Care Completed NCT00278447 Phase 3
154 Adolescent Outpatient and Continuing Care Study Completed NCT01381133 Phase 3
155 Telephone Enhancement Procedure (TELE) for Continuing Care Completed NCT00067171 Phase 3
156 Motivational Enhancement Therapy (MET) to Improve Treatment Utilization in Pregnant Substance Users Completed NCT00078143 Phase 3
157 A New School-based Drug Prevention Programme for Teenagers: Interventions That Target Personality Risk for Substance Abuse and Mental Illness Completed NCT00344474 Phase 2, Phase 3
158 Psychopharmacotherapy in Multiple Substances Abuse / Dependence - the Pharmacological and Immunological Approach to the New Indication of Memantine Completed NCT01189214 Phase 3 Memantine
159 Voucher-Based Incentives in a Prevention Setting Completed NCT00607269 Phase 2, Phase 3
160 Translation of CDC and NIDA Programs to Prevent HIV/AIDS Among Persons With Serious Mental Illness Completed NCT00447720 Phase 3
161 Smoking Cessation Treatment With Transdermal Nicotine Replacement Therapy Completed NCT00067158 Phase 3 nicotine transdermal system
162 Cognitive Behavioral Interventions That Target Personality Risk for Substance Abuse and Mental Illness: Delivery by Educational Professionals Completed NCT00776685 Phase 2, Phase 3
163 A Phase III Randomized Study to Evaluate the Efficacy of a Network-Oriented Peer Education Intervention for the Prevention of HIV Transmission Among Injection Drug Users and Their Network Members Completed NCT00038688 Phase 3
164 A Proof of Concept Study of Icariin for Bipolar Disorder and Co-Occurring Substance Use Disorders Completed NCT01979133 Phase 3 Icariin
165 Depot Pharmacotherapies for Opioid-Dependent Offenders: Outcomes and Costs Completed NCT02110264 Phase 3 XR-NTX
166 "Effectiveness of a Brief Intervention for Substances Consumption Linked to the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): A Randomized Control Trial in Chilean Primary Care." Completed NCT01573416 Phase 3
167 Combining Behavioral Treatment With Agonist Maintenance Completed NCT00000311 Phase 3 Buprenorphine;methadone
168 Motivational Incentives for Enhanced Drug Abuse Recovery: Drug Free Clinics Completed NCT00033007 Phase 3
169 Job Seekers Training for Patients With Drug Dependence Completed NCT00102362 Phase 3
170 Buprenorphine Maintenance for Cocaine Abusing Opioid Addicts Completed NCT00000216 Phase 3 Buprenorphine
171 Health Promotion and Public Safety: Community-based Collaborative Services to Addicted Offenders Completed NCT01843751 Phase 3 buprenorphine/naloxone
172 CS1008 A&B Eff/Safety Trial of BUP/NX for the Treatment of Opiate Dependence Completed NCT00015171 Phase 3 Buprenorphine/naloxone
173 Integrated Cognitive Behavioral Therapy for Co-Occurring PTSD and Substance Use Disorders Completed NCT01457404 Phase 3
174 Familias Unidas Stage III Study: Preventing Substance Abuse in Hispanic Youth Completed NCT01038206 Phase 2, Phase 3
175 Comparing Treatments for HIV-Infected Opioid and Alcohol Users in an Integrated Care Effectiveness Study Completed NCT01908062 Phase 3 Extended Release Naltrexone
176 Effectiveness of Assertive Continuing Care for Youth Completed NCT01085188 Phase 3
177 A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety, Tolerability, and Efficacy of Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL Completed NCT02696434 Phase 3 Naltrexone;Placebo;Buprenorphine
178 Smoking-Cessation and Stimulant Treatment (S-CAST): Evaluation of the Impact of Concurrent Outpatient Smoking-Cessation and Stimulant Treatment on Stimulant-Dependence Outcomes Completed NCT01077024 Phase 3
179 A Phase III Trial to Determine the Efficacy of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand Completed NCT00006327 Phase 3
180 Treating the Partners of Drug Using Pregnant Women: Stage II Completed NCT00496990 Phase 2, Phase 3
181 The Role of Sleep in the Treatment of Cannabis Use Disorders Completed NCT01685073 Phase 2, Phase 3 Zolpidem extended-release
182 Acute and Long-term Effects of Intranasal Oxytocin in Alcohol Withdrawal and Dependence: A Prospective Randomized Parallel Group Placebo-controlled Trial Completed NCT02903251 Phase 3 intranasal oxytocin spray
183 A Bundled Rapid HIV/HCV Testing Intervention to Increase Receipt of Test Results Completed NCT02355080 Phase 2, Phase 3
184 Adolescent Drug and HIV Prevention in South Africa Completed NCT00336180 Phase 2, Phase 3
185 Effectiveness of Motivational Interviewing Supervision in Community Programs Completed NCT01586676 Phase 2, Phase 3
186 HIV Rapid Testing and Counseling in Drug Abuse Treatment Programs in the U.S. Completed NCT00809445 Phase 3
187 Comparing Internet and In-Person Brief Cognitive Behavioral Therapy of Insomnia Completed NCT01549899 Phase 3
188 Improving Primary Care in Patients With Mental Disorders Completed NCT00183313 Phase 3
189 Long-term Effects of Intranasal Oxytocin in Alcohol Withdrawal and Dependence: Follow-up of a Randomized Controlled Trial Completed NCT03339024 Phase 3 intranasal oxytocin spray
190 Recovery Housing For Drug Dependent Pregnant Women Completed NCT00497302 Phase 2, Phase 3
191 Double-Blind, Placebo Controlled Trial of Prometa Pharmacotherapy for the Treatment of Methamphetamine Abuse Completed NCT00260481 Phase 2, Phase 3 Prometa;Placebo
192 Making Alcoholics Anonymous Easier: A Group TSF Approach Completed NCT01382316 Phase 3
193 An Open-Label Multicenter Study Assessing the Long-Term Safety of a Once-Weekly and Once-Monthly, Long-Acting Subcutaneous Injection Depot of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder Completed NCT02672111 Phase 3 CAM2038 q1w or q4w exposure to SL BPN/NX;CAM2038 q1w or q4w new to BPN treatment
194 A Phase III, Randomized, Double-Blind, Active-Controlled, Parallel Group, Multi-center Trial Assessing the Efficacy and Safety of a Once-Weekly and Once-Monthly, Long-Acting Subcutaneous Injectable Depot of Buprenorphine (CAM2038) in Treatment of Adult Outpatients With Opioid Use Disorder Completed NCT02651584 Phase 3 CAM2038 SC injection;SL BPN/NX tabs;placebo SC injections;SL placebo tablets
195 Pharmacotherapeutic Intervention to Improve Treatment Engagement Among Alcohol-dependent Veterans After Hospital Discharge Completed NCT01856712 Phase 3 Naltrexone
196 Brief Intervention to Reduce STDs in ER Drug Users Completed NCT01379599 Phase 3
197 Controlled Trial of Risperidone and Divalproex Sodium With MRI Assessment of Affected Circuitry in Pre and Post Treatment in Pediatric Bipolar Completed NCT00176202 Phase 3 Divalproex Sodium;risperidone
198 An Randomized Controlled Trial (RCT) of the Trauma Recovery and Empowerment Model Completed NCT00183716 Phase 3
199 Effectiveness Trial of an Adolescent Depression Prevention Program Completed NCT00904891 Phase 2, Phase 3
200 Transitional Case Management Study Completed NCT00264329 Phase 3
201 Treating Violence-Prone Substance Use Disorder Patients Completed NCT00700973 Phase 2, Phase 3
202 Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder Completed NCT03169816 Phase 2, Phase 3 Lorcaserin;Placebo
203 Antidepressant Treatment to Reduce HIV Risk Among IDUs Completed NCT00183768 Phase 3
204 Maintaining HIV Risk Reduction Among Needle Exchangers Completed NCT00228007 Phase 3 Antidepressant Medication
205 Quetiapine XR in the Treatment of Comorbid Generalized Anxiety Disorder in Bipolar Depression With or Without Substance Use Disorder Completed NCT00671853 Phase 3 Quetiapine XR;Placebo for quetiapine XR
206 Initialization of Methadone in Primary Care; a Randomized Intervention Research for Preventing HCV Transmission Practices. ANRS Methaville Completed NCT00657397 Phase 3 Methadone
207 Stimulant Abuser Groups to Engage in 12-Step (STAGE-12): Evaluation of a Combined Individual-Group Intervention to Reduce Stimulant and Other Drug Use by Increasing 12-Step Involvement Completed NCT00573183 Phase 3
208 Naltrexone Naltrexone Implants as an Aid in Preventing Relapse Following Inpatient Treatment for Opioid Addiction - a Randomised Study Completed NCT00521157 Phase 2, Phase 3 Go Medical Naltrexone implants
209 Child/Adolescent Anxiety Multimodal Treatment Study Completed NCT00052078 Phase 3 Sertraline (SRT);Placebo
210 Community-Based Cognitive Therapy for Suicide Attempters Completed NCT00081367 Phase 3
211 Combination Therapy in Dual Diagnosis Rapid Cycling Bipolar Disorder Completed NCT00221975 Phase 3 Divalproex;Lamotrigine;Lithium
212 Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults Completed NCT01052662 Phase 2, Phase 3 Memantine;Memantine;Placebo
213 Reducing Heavy Drinking to Optimize HIV/AIDS Treatment and Prevention Completed NCT01227044 Phase 2, Phase 3 Naltrexone
214 Forensic Assertive Community Treatment: An Emerging Model of Service Delivery Completed NCT01313052 Phase 3
215 Can Maternal Acupuncture for Chemically Dependent Pregnant Women Reduce the Severity of Neonatal Abstinence Syndrome? - A Randomized Controlled Trial Completed NCT00225316 Phase 3
216 An Open-Label, Long-Term Safety and Tolerability Study of Depot Buprenorphine (RBP-6000) in Treatment-Seeking Subjects With Opioid Use Disorder Completed NCT02510014 Phase 3 SUBOXONE sublingual film;RBP-6000
217 Cocaine Use Reduction With Buprenorphine (CURB) Completed NCT01402492 Phase 2, Phase 3 Buprenorphine + Naltrexone;Placebo + Naltrexone
218 Project 1: Clinical Neurobiology of Serotonin and Addiction Completed NCT00732901 Phase 2, Phase 3 Escitalopram;Placebo
219 A Trial to Reduce Hepatitis C Among Injection Drug Users Completed NCT00218192 Phase 3
220 Parallel Groups Study of Divalproex Sodium (Depakote) for Irritable, Explosive Adults & Adolescents Completed NCT00218114 Phase 3 Divalproex Sodium;Placebo
221 Randomized Trial of a Smoking Cessation Program for Persons With SMI Completed NCT00960375 Phase 2, Phase 3
222 Randomised, Controlled, Parallel Clinical Trial on the Efficacy of Pharmacogenetic Information Obtained With NEUROFARMAGEN in the Treatment of Patients With Mental Disorders Completed NCT02529462 Phase 3 Treatment As Usual
223 Fluoxetine for Anxious Children Completed NCT00000381 Phase 3 Fluoxetine
224 Maternal Opioid Treatment: Human Experimental Research Completed NCT00271219 Phase 3 Methadone;Buprenorphine
225 Young Sexually Abused Children: Optimal CBT Strategies Completed NCT00073684 Phase 3
226 Promoting Child Mental Health: RCT of Home Visiting Completed NCT00218751 Phase 2, Phase 3
227 Adaptive Treatment for Alcohol and Cocaine Dependence Completed NCT01032135 Phase 2, Phase 3 medication management
228 A Two-Phase Randomized Controlled Clinical Trial of Buprenorphine/Naloxone Treatment Plus Standard Medical Management or Enhanced Medical Management for Opioid Analgesic Dependence Completed NCT00316277 Phase 3
229 Early Re-Intervention (ERI) Experiment 2 Completed NCT01153594 Phase 3
230 Reinforcement-Based Treatment for Pregnant Drug Abusers Completed NCT01177982 Phase 2, Phase 3
231 Atypical Antipsychotics for Continuation and Maintenance Treatment After an Acute Manic Episode Completed NCT01977300 Phase 3 Valproate;Lithium;Risperidone;Olanzapine
232 CSP #494 - A Randomized Clinical Trial of Cognitive-Behavioral Treatment for PTSD in Women (PTSD) Completed NCT00032617 Phase 3
233 Naltrexone & SSRI in Alcoholics With Depression/PTSD Completed NCT00338962 Phase 3 paroxetine;desipramine;Naltrexone;Placebo
234 Dopamine Transporter (DAT) in Pharmacological Treatments of Cocaine Dependence. CAIMAN (Cocaine Addiction Imaging Medications and Neurotransmitters) Study Completed NCT00701532 Phase 3 Modafinil and PET (brain imaging);placebo
235 Group Cognitive Behavioral Therapy (CBT) For Depression in Clients With Alcohol and Other Drug (AOD) Disorders Completed NCT01191788 Phase 2, Phase 3
236 Combination Pharmacotherapy With Chantix & Bupropion for Smoking Cessation (ChanBan) Completed NCT00587769 Phase 3 Bupropion SR & Varenicline
237 Behavioral Naltrexone Therapy (BNT) for Promoting Adherence to Oral Naltrexone (BNT-oral) vs Extended Release Injectable Depot Naltrexone (Depot-BNT); a Randomized Trial Completed NCT00577408 Phase 3 depot naltrexone;Oral Naltrexone
238 A New Pharmacotherapy for Alcohol Dependence: Olanzapine Completed NCT00746785 Phase 3 2.5 mg Olanzapine;5mg Olanzapine;placebo
239 Efficacy/Effectiveness of Unhealthy Drug Use Screening/Brief Intervention Models Completed NCT00876941 Phase 3
240 A Stage II Efficacy Study of Cognitive Behavioral Therapy for PTSD in Community Addiction Treatment Completed NCT01457391 Phase 3
241 NHLBI/NICHD Collaborative Studies of Asthma in Pregnancy Completed NCT00000578 Phase 3 theophylline;beclomethasone
242 Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders Completed NCT00221403 Phase 3 Risperidone Valproate
243 Firefighter Aged Garlic Extract Investigation With CoQ10 as a Treatment for Heart Disease (FAITH) Completed NCT00860847 Phase 3
244 Using a YMCA Exercise Program to Enhance Nicotine Dependence Treatment for Women Completed NCT01615380 Phase 2, Phase 3
245 Pharmacotherapy for Alcohol Consumption in HIV Infected Women: Randomized Trial Completed NCT01625091 Phase 3 Naltrexone;Placebo
246 Prospective Randomized Pilot Study of Daily Consensus Interferon (CIFN) and Ribavirin for 52 Wks vs Extended Duration 72 Wks Based on Virologic Response for the Initial Treatment of Difficult-to-treat Patients With Chronic HCV Genotype 1 Completed NCT00211692 Phase 3 consensus interferon (Interferon Alfacon-1) and ribavirin;Consensus Interferon alfa (CIFN) and ribavirin
247 A Novel Approach to Cardiovascular Health by Optimizing Risk Management (ANCHOR): A Primary Prevention Initiative Examining The Impact Of Global Risk Factor Assessment & Management On Health Care In Nova Scotia Completed NCT01620996 Phase 3
248 Child and Adolescent Trial for Cardiovascular Health (CATCH) Completed NCT00000467 Phase 3
249 The Treatment And Prevention (TAP) Study: Treating People Who Inject Drugs (PWID) in Community-based Settings Using a Social Network Approach Recruiting NCT02363517 Phase 3 Sofosbuvir/ledispasvir fixed dose combination (SOF + LDP)
250 Bupropion-Enhanced CM for Cocaine Dependence Recruiting NCT02111798 Phase 2, Phase 3 Bupropion XL;placebo
251 NTNU Intranasal Naloxone Trial - a Double Blinded, Double Dummy, Randomized Controlled Trial of Intranasal Naloxone for Pre-hospital Use Recruiting NCT03518021 Phase 3 Naloxone, intranasal;placebo, intranasal;Naloxone, intramuscular;placebo, intramuscular
252 Substance Misuse To Psychosis for Stimulants (SToP-S)--An Early Assertive Pharmacotherapy Intervention Study Recruiting NCT03485417 Phase 2, Phase 3 Aripiprazole;Paliperidone
253 Study of the Efficacy of N-acetylcysteine (NAC) on Impulse Control Disorders (TCI) Induced by Dopaminergic Treatments in Parkinson's Disease Recruiting NCT03146130 Phase 3
254 Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users (PrEPSteps) Recruiting NCT03512418 Phase 3 Truvada
255 Non-Opiate Treatment After Prenatal Opiate Exposure to Prevent Postnatal Injury to the Young Brain Recruiting NCT03396588 Phase 3 Clonidine;Morphine
256 Effect of Intraoperative and Post-operative Opioids on Persistent Opioid Use in the Surgical Patient Recruiting NCT03367988 Phase 2, Phase 3 Opioid Anesthesia;Opioid-free Anesthesia
257 Improving Treatment Outcomes for Prescription Opioid Dependence Recruiting NCT02543944 Phase 2, Phase 3 Gabapentin;Buprenorphine;Clonidine;Naltrexone (oral);Naltrexone (depot);Placebo
258 A Randomized, Double-Blind, Placebo-Controlled, Multi-Site Phase 3 Study of the Efficacy and Safety of Manualized MDMA-Assisted Psychotherapy for the Treatment of Severe Posttraumatic Stress Disorder Recruiting NCT03537014 Phase 3 MDMA;Placebo
259 Multimodal Anesthesia and Analgesia for Total Shoulder and Reverse Total Shoulder Arthroplasty: A Randomized Controlled Trial Recruiting NCT03586934 Phase 3 Acetaminophen;Celecoxib 200mg;Celecoxib 400 mg;Ropivacaine;Ketorolac;Acetaminophen Injectable Product;Oxycodone;Tramadol;Morphine Injectable Solution;hydrocodone bitartrate and acetaminophen;Morphine;Oxycodone Hydrochloride;Meloxicam
260 Preventing Injection Initiation: The Change the Cycle Randomized Controlled Trial. Active, not recruiting NCT02774954 Phase 3
261 HIV & Drug Abuse Prevention for South African Men Active, not recruiting NCT02358226 Phase 3
262 Impact of Enhancements to Smartphone Based Continuing Care for Alcohol Dependence Active, not recruiting NCT02681406 Phase 2, Phase 3
263 Metformin for the Prevention of Episodic Migraine: a Randomized, Double-blind, Placebo-controlled, Crossover Study Active, not recruiting NCT02593097 Phase 3 Metformin;Matching Placebo
264 The Efficacy of Suvorexant in the Residential Treatment of Patients With Substance Use Disorder and Insomnia: A Pilot Open Trial Enrolling by invitation NCT03412591 Phase 2, Phase 3 Suvorexant 20 mg
265 NIDA CTN Protocol 0080: Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs): Infant Neurodevelopmental Outcomes (INO) Sub-study Not yet recruiting NCT03911739 Phase 3 Buprenorphine Injection;Buprenorphine Sublingual Product
266 Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs): a Pragmatic Randomized Trial Comparing Extended-release and Daily Buprenorphine Formulations Not yet recruiting NCT03918850 Phase 3 Buprenorphine Injection;Buprenorphine Sublingual Product
267 NIDA CTN Protocol 0080: Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs): a Pragmatic Randomized Trial Comparing Extended-release and Daily Buprenorphine Formulations: Conceptual Model Assessments (CMA) Sub-study Not yet recruiting NCT03911466 Phase 3 Buprenorphine Injection;Buprenorphine Sublingual Product
268 Effectiveness of an Integrated Treatment to Address Smoking Cessation and Anxiety/ Depression in People Living With HIV Not yet recruiting NCT03904186 Phase 3
269 A Randomized, Double-Blind, Placebo-Controlled, Multi-Site Phase 3 Study of the Efficacy and Safety of Manualized MDMA-Assisted Psychotherapy for the Treatment of Severe Posttraumatic Stress Disorder Not yet recruiting NCT04077437 Phase 3 MDMA;Placebo
270 Naltrexone Implants as an Aid in Preventing Relapse Following Inpatient Treatment for Opioid Addiction. Terminated NCT00269607 Phase 2, Phase 3 Implantation of naltrexone implants
271 A Randomized, Double-blind, Double-dummy, Controlled Trial of Lithium Versus Paroxetine in Subjects With Major Depression Who Have a Family History of Bipolar Disorder or Completed Suicide - a Pilot Study Terminated NCT00400088 Phase 3 paroxetine;lithium
272 Advancing Adolescent Screening and Brief Intervention Protocols in Primary Care Settings Withdrawn NCT01523444 Phase 3
273 Integration of Internet-facilitated Screening, Brief Intervention, Referral to Treatment (iSBIRT) for Teen Drug Use Into a Pediatric Network Withdrawn NCT01454206 Phase 2, Phase 3
274 Primary Care Internet-Based Depression Prevention for Adolescents (CATCH-IT) Withdrawn NCT01228890 Phase 3
275 Vortioxetine for the Treatment of Major Depression and Neuropsychiatric Co-morbidities After Traumatic Brain Injury (TBI) Withdrawn NCT02845349 Phase 3 Vortioxetine;Placebo
276 Mindfulness and Acceptance Group Therapy for Substance Use Unknown status NCT01751542 Phase 2
277 Phase 2 RCT of Jail-Based Impact of Crime Intervention to Reduce Recidivism, Substance Abuse and HIV Risk Behavior Unknown status NCT01378936 Phase 2
278 An Integrated Treatment for Comorbid PTSD and Substance Abuse in Adolescents Unknown status NCT01825694 Phase 1, Phase 2
279 Computerized Working Memory Training in Adults With Substance Abuse and Executive Function Deficits: A Randomised Controlled Trial. Unknown status NCT02068261 Phase 2
280 Pilot Evaluation of the Re-Entry Values and Mindfulness Program (REVAMP) With Jail Inmates Unknown status NCT01378923 Phase 1, Phase 2
281 Addiction Treatment Dropout Prevention - Impact of Online Patient Feedback (OQ-45.2) to Therapist Unknown status NCT01891045 Phase 2
282 Trial of Impact of Crime Group Intervention for Jail Inmates Unknown status NCT01380977 Phase 1, Phase 2
283 Counseling Conditions for Thrice Weekly Buprenorphine in a Primary Care Clinic Unknown status NCT00023283 Phase 2 Buprenorphine
284 Distress Tolerance Treatment for Substance Users Unknown status NCT01741415 Phase 2
285 Prevention of Drug Use in Adolescence: Intervening in Parenting Styles Unknown status NCT02386280 Phase 1, Phase 2
286 A Stage 1 Study of Community Reinforcement and Family Training for Treatment Drug Abuse Treatment Retention/HIV Risk Reduction Unknown status NCT00609089 Phase 1, Phase 2
287 Computerized Stage-Matched Intervention for Juvenile Offenders Unknown status NCT02023827 Phase 2
288 ENGAGE - Meeting Mental Health Needs of Complex Comorbid Patients Attending A&E Following a Suicide Attempt. A Pilot Study. Unknown status NCT00980824 Phase 1, Phase 2
289 Behavioral Trial for the Treatment of Methamphetamine Dependence Unknown status NCT00033124 Phase 2
290 A Dose Ranging Study of Modafinil for Methamphetamine Dependence Unknown status NCT00630097 Phase 2 modafinil
291 Psychotherapy Enhancement for TC Retention Unknown status NCT00086398 Phase 2
292 Carisbamate as a Potential Treatment for Alcohol Dependence Unknown status NCT02435381 Phase 1, Phase 2 Carisbamate;Placebo
293 RTC of Web Versus In-Person SUD and Comorbidity Treatment Unknown status NCT01529047 Phase 2
294 Sublingual Buprenorphine for Chronic Pain in Patients at Risk for Drug Abuse Unknown status NCT00612287 Phase 2 buprenorphine
295 A Double-Blind, Placebo-Controlled, Randomized, Parallel Group Study to Assess Dopamine Receptor Modulation With Rotigotine to Enhance Opioid Analgesia Using the Oral Surgery Model of Acute Pain in Healthy Volunteers Unknown status NCT02123979 Phase 2 Neupro® transdermal patch/placebo
296 Web-based CBT for Substance Misusing and PTSD Symptomatic OEF/OIF Veterans Unknown status NCT01710943 Phase 1, Phase 2
297 CANDIS -Targeted Treatment for Cannabis Disorders Unknown status NCT00252980 Phase 2
298 A Double Blind Placebo Controlled Trial of Autologous Platelet Rich Plasma (PRP) Peri-urethral and Clitoral Injections for the Treatment of Female Orgasmic Disorder Unknown status NCT03189238 Phase 2
299 Effectiveness of Rehabilitation (Phasic Alerting and Visual Spatial Scanning Training) on the Recovery of Patients Post Right Stroke With Unilateral Spatial Neglect: Using Functional Imaging PET and Standardized Neurobehavioral and Functional Tests Unknown status NCT00305513 Phase 2
300 Family Based Intervention for Adolescent Suicide Attempters Unknown status NCT00692302 Phase 1, Phase 2
301 A Phase II Study of Gefitinib in Benefited Patients With Asymptomatic Brain Metastasis Advanced Non-Small Cell Lung Cancer by Chemotherapy Unknown status NCT00614809 Phase 2 gefitinib
302 Clinical Trial of the Adrenergic Alpha-1 Antagonist Prazosin for Alcohol Dependence Unknown status NCT00762710 Phase 2 Prazosin medication;Placebo medication
303 A Randomized Control Trial to Determine the Effectiveness of Trauma Focused Cognitive Behavioral (TF-CBT) Among Children in Lusaka, Zambia Unknown status NCT01624298 Phase 2
304 Remote Brief Intervention and Referrals to Treatment Service for Alcohol Unknown status NCT02622984 Phase 2
305 rTMS Over the Supplementary Motor Area for Treatment-resistant Obsessive-compulsive Disorder: a Multicenter, Double-blind, Controlled Trial. Unknown status NCT03211221 Phase 2
306 Randomized Evaluation of Octreotide Versus Compazine for Emergency Department Treatment of Migraine Headache Unknown status NCT00274170 Phase 1, Phase 2 Octreotide
307 The Efficacy of a Cognitive-Behavioural Intervention in Deliberate Self-Harm Patients: A Randomized Controlled Trial Among Adolescents and Young Adults Unknown status NCT00169884 Phase 2
308 Efficacy of Group Treatment for Hispanic Adolescents - RCT Completed NCT01018654 Phase 2
309 Carbamazepine Treatment of Cocaine Dependence Completed NCT00000242 Phase 2 Carbamazepine
310 Cholesterol and Fatty Acids in Cocaine Addiction Relapse Completed NCT00312455 Phase 2 Pro-eicosapentaenoic acid (EPA);Pro-docosapentaenoic acid (DPA);Placebo
311 Effectiveness of Self-Help for Dually-Diagnosed Persons Completed NCT00218582 Phase 1, Phase 2
312 Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial Completed NCT00617201 Phase 2 atomoxetine;placebo
313 Navigating My Journey (NmJ): A Relapse Prevention Program for Adolescents -- Field Trial Completed NCT02125539 Phase 2
314 Matching, Outcomes and Costs in Substance Abuse/Psychiatric Treatment Completed NCT00012727 Phase 2
315 Cognitive Remediation and Work Therapy in the Initial Phase of Substance Abuse Treatment Completed NCT01410110 Phase 2
316 Evaluating Alternative Aftercare Models for Ex-offenders Completed NCT01586689 Phase 2
317 Abstinence-Linked Money Management Completed NCT00536900 Phase 2
318 Testing a Promising Treatment for Youth Substance Abuse in a Community Setting Completed NCT02130479 Phase 1, Phase 2
319 RCT of Auricular Acupuncture in Substance Abuse: Effects on Anxiety, Sleep, Drug Use and Use of Addiction Treatment Services. A Randomized Controlled Study Completed NCT02604706 Phase 2
320 Drug Treatment for Transplant Candidates Completed NCT00249652 Phase 1, Phase 2
321 Evaluation of a Harm Reduction Treatment for Methamphetamine-Using Men Who Have Sex With Men (MSM) Completed NCT01129401 Phase 1, Phase 2
322 Behavioral Treatment of Drug Abuse in SPMI Patients Completed NCT00295139 Phase 2
323 Computer Based Training in Cognitive Behavioral Therapy Web-based Completed NCT01442597 Phase 1, Phase 2
324 Computer-based Brief Intervention for Perinatal Drug, Alcohol, and Tobacco Abuse Completed NCT00685074 Phase 1, Phase 2
325 Randomized Trial of Fathers for Change: An Intervention for Fathers With Co-Occuring Domestic Violence and Substance Abuse Completed NCT01385553 Phase 1, Phase 2
326 Stage II Research on Outpatient Treatment for Adolescents With Comorbidity Completed NCT01117753 Phase 2
327 Women's Prison TC: Outcomes, Process & Economic Analysis Completed NCT00249561 Phase 1, Phase 2
328 The STIRR Intervention for Dually Diagnosed Clients Completed NCT00316303 Phase 2 Twinrix
329 Evaluation of Treatments for Homeless Youth: CRA, MET and Case Management Completed NCT01143792 Phase 2
330 ASI-MV Solutions: A Tailored Program for Substance Abusers in Early Recovery Completed NCT01948440 Phase 2
331 Monitoring and Feedback in Substance Abuse Treatment Completed NCT01465490 Phase 1, Phase 2
332 Medical Office Intervention for Adolescent Drug Use Completed NCT00229983 Phase 2
333 Rapid Benzodiazepine Detoxification Using Flumazenil Completed NCT00000246 Phase 2 Flumazenil
334 Motivating Treatment Seeking and Behavior Change by Untreated Military Personnel Abusing Alcohol or Drugs Completed NCT01128140 Phase 2
335 A Double-Blind, Randomized, Placebo and Active-Controlled, Six-Period Crossover Study to Evaluate the Likeability, Safety, and Abuse Liability of NRP104 in Healthy Adult Volunteers With Histories of Stimulant Abuse Completed NCT00248092 Phase 1, Phase 2 NRP104
336 A Double-Blind Placebo- and Active-Controlled, Single-Dose Crossover PD and PK Study to Evaluate the Safety, Tolerability and Abuse Liability of IV Administered NRP104 25 mg and 50 mg in Adult Volunteers With Histories of Stimulant Abuse Completed NCT00247572 Phase 2 NRP104
337 HIV Prevention Partnership in Russian Alcohol Treatment Completed NCT00183118 Phase 1, Phase 2
338 Group IPT for Women Prisoners With Comorbid Substance Use and Depression Completed NCT00606996 Phase 2
339 Prefrontal Modulation by Repetitive Bilateral Transcranial Direct Current Stimulation (tDCS) in Crack-cocaine Addicted Inpatients. Completed NCT02091167 Phase 2
340 Mindfulness Based Relapse Prevention: Efficacy and Mechanisms Completed NCT01159535 Phase 1, Phase 2
341 Substance Treatment Referral System Completed NCT01488630 Phase 2
342 Adolescent Involvement in Parental Substance Abuse Treatment: Evaluation of EBFT Completed NCT01576393 Phase 1, Phase 2
343 Flupenthixol Decanoate in Methamphetamine Smoking Completed NCT00000241 Phase 2 Flupenthixol
344 Effectiveness of Advisor - Teller Money Manager (ATM) Completed NCT00105768 Phase 1, Phase 2
345 Clinical Trial to Determine the Effect of a Brief Behavioral Intervention in Reducing Drug Misuse Among an Emergency Department Population Completed NCT01124591 Phase 2
346 Memory Reconsolidation Blockade for Treating Drug Addiction: a Feasibility Study Completed NCT01634347 Phase 2 Propranolol and memory reactivation;Placebo and memory reactivation
347 Risk Reduction for Urban Substance Using Men Who Have Sex With Men (MSM) Completed NCT01327898 Phase 2
348 Contingency Management in the Delivery of HAART to Drug Users in Chennai, India Completed NCT01031745 Phase 2
349 Relational Parenting Group for Opioid-Addicted Mothers Completed NCT00319241 Phase 2
350 Indirect Assessment and Intervention for Perinatal Drug Use Completed NCT01650675 Phase 2
351 An Integrated Pharmacological and Psychological Approach to Young People With Comorbid Depression and Substance Abuse Completed NCT00232284 Phase 2 sertraline
352 The Dynamic Assessment and Referral System for Substance Abuse: Evaluation Completed NCT01153373 Phase 2
353 Novel Medications for Opiate Detoxification Completed NCT00000279 Phase 2 Clonidine
354 CRAFT Behavior Therapy Phase 2 Study: Treatment Entry Component Completed NCT00842036 Phase 2
355 Aripiprazole Treatment for Methamphetamine Dependence Among High-risk Individuals Completed NCT00497055 Phase 2 Aripiprazole;Placebo
356 Adherence to HIV Therapy in Heroin Addicts: Oral vs. Extended Release Naltrexone Completed NCT01101815 Phase 2 Oral Naltrexone;Naltrexone Implant
357 Pilot Study of Acceptability of Bupropion Treatment for Methamphetamine Dependence Among Men Who Have Sex With Men. Completed NCT00318409 Phase 2 Bupropion;Placebo
358 Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations Completed NCT01246401 Phase 1, Phase 2 Extended-Release Naltrexone
359 CRAFT: Helping Parents Initiate and Support Their Adolescent's Treatment Completed NCT01344382 Phase 1, Phase 2
360 Abstinence-Linked Money Management Multisite Completed NCT01327586 Phase 2
361 Development of Violence Therapy for Substance Abusers Completed NCT00551863 Phase 1, Phase 2
362 Buprenorphine Maintenance for Opiate Dependence Completed NCT00000357 Phase 2 Buprenorphine
363 Pharmacokinetics of LAAM in Methadone Patients Completed NCT00000356 Phase 2 LAAM
364 Efficacy/Safety Trial of Buprenorphine/Nx for Opiate Dependence Completed NCT00000353 Phase 2 Buprenorphine/naloxone
365 Effects of Dextromethorphan on Opioid Tolerance in Methadone Patients Completed NCT00000352 Phase 2 Dextromethorphan
366 Buprenorphine Maintenance Dose Schedule and Treatment Setting Completed NCT00000319 Phase 2 Buprenorphine
367 Buprenorphine Maintenance Dose Schedule and Treatment Setting: Pilot Completed NCT00000318 Phase 2 Buprenorphine
368 Pharmacotherapy for Schizophrenic Drug Users Completed NCT00000281 Phase 2
369 Flupenthixol and Haloperidol for Treating Cocaine Abuse Schizophrenics Completed NCT00000274 Phase 2 Flupenthixol
370 Pergolide Treatment for Substance Abusers Completed NCT00000269 Phase 2 Pergolide
371 Evaluation of a Desipramine Ceiling in Cocaine Abuse Completed NCT00000245 Phase 2 Desipramine
372 Pharmacotherapy and Intensive Treatment of Drug Abuse Completed NCT00000217 Phase 2 Carbamazepine
373 Treatment Efficacy for Drug Abuse and AIDS Prevention Completed NCT00000211 Phase 2 Buprenorphine
374 Treatment Efficacy for Drug Abuse and AIDS Prevention Completed NCT00000210 Phase 2 Buprenorphine
375 Psychopharmacology of Adolescents With AUD and ADHD Completed NCT00029614 Phase 2 Atomoxetine
376 Mirtazapine to Reduce Methamphetamine Use Among MSM With High-risk HIV Behaviors Completed NCT00497081 Phase 2 mirtazapine;placebo
377 HEART to HAART: Smartphone Intervention to Improve HAART Adherence for Drug Users Completed NCT01413529 Phase 2
378 Enhancing Prevention Capacity With Developmental Assets and Getting to Outcomes Completed NCT00780338 Phase 2
379 Reinforcement of Abstinence and Attendance in Substance Abuse Treatment Completed NCT00288886 Phase 2
380 Varenicline for Methamphetamine Dependence: Phase II Clinical Trial Completed NCT01365819 Phase 2 Varenicline;Placebo
381 A Laboratory Model for Heroin Abuse Medications Completed NCT00000273 Phase 2 opiates
382 Advancing Varenicline as a Treatment for Cannabis Use Disorder Completed NCT02892110 Phase 2 Varenicline;Placebo
383 Methyphendidate in the Treatment of Cocaine Dependent Patients With Adult ADHD Completed NCT00015223 Phase 2 Methylphenidate
384 Integrated Intervention for Substance Abusers With Depressive Disorders Completed NCT00018655 Phase 2
385 Therapeutic IVR to Augment CBT in Alcohol Dependence Completed NCT00132795 Phase 2
386 Enhancing Juvenile Drug Court Outcomes With Evidence-Based Practices Completed NCT01266109 Phase 2
387 Evaluation of Web-Based Recovery Monitoring With Clinical Alerts Completed NCT01465555 Phase 1, Phase 2
388 Culturally Informed Family Based Treatment of Adolescents: A Randomized Trial Completed NCT01823250 Phase 2
389 Dextroamphetamine as an Adjunct in Cocaine Treatment Completed NCT00000304 Phase 2 Dextroamphetamine;D-Amphetamine;Placebo
390 Effects of Alcohol History on Effects of Sevoflurane and Nitrous Oxide Completed NCT00000261 Phase 2 30% Nitrous oxide;0.2% sevoflurane;0.4% sevoflurane;0.6% sevoflurane
391 Differential Acute Tolerance Development to Effects of Nitrous Oxide Completed NCT00000255 Phase 2 Nitrous oxide
392 Isoflurane at Subanesthetic Concentrations Completed NCT00000254 Phase 2 40% Nitrous oxide;0.2% isoflurane;0.4% isoflurane;0.6% isoflurane
393 Lack of Acute Tolerance Development to Effects of Nitrous Oxide Completed NCT00000252 Phase 2 0% N2O;10% N2O;20% N2O;30% N2O;40% N2O
394 Effects of Subanesthetic Concentrations of Isoflurane/Nitrous Oxide Completed NCT00000251 Phase 2 30% N2O;0.2% isoflurane;0.4% isoflurane
395 Effects of Subanesthetic Concentrations of Nitrous Oxide Completed NCT00000249 Phase 2 20% N2O;30% N2O;40% N2O
396 Cognitive Training in Adolescents During Treatment for Substance Use Disorders Completed NCT01948674 Phase 2
397 Phase 2, Double-Blind, Placebo Controlled Trial of Cabergoline for the Treatment of Cocaine Dependence Completed NCT00033111 Phase 2 Cabergoline;Placebo
398 Phase 2, Double-Blind, Placebo-Controlled Trial of Reserpine for the Treatment of Cocaine Dependence Completed NCT00033033 Phase 2 Reserpine
399 Efficacy of Nefazodone in Cocaine Dependent Subjects Completed NCT00015210 Phase 2 Nefazodone
400 Effects of Cognitive Training in Methadone Maintenance Patients Completed NCT01271413 Phase 2
401 Medications Development for Drug Abuse Disorders Completed NCT01188421 Phase 1, Phase 2 Buprenorphine/naloxone;Clonidine;Tramadol ER
402 Brief Intervention in At-Risk First-time Mothers Completed NCT00230009 Phase 1, Phase 2
403 A Randomized Controlled Trial Comparing (1) a Combined Treatment of CBT for Substance Use Disorders (SUD) and Trauma-focused Structured Writing Therapy With (2) CBT for SUD Alone in Patients With Comorbid SUD and PTSD Completed NCT00763542 Phase 2
404 Interactive Motivational Media for Perinatal Drug Abuse Completed NCT00230048 Phase 2
405 Building Outcomes With Observation-Based Supervision: An FFT Effectiveness Trial Completed NCT01614015 Phase 2
406 Evaluating Alternative Aftercare Models for Ex-Offenders Completed NCT00664092 Phase 2
407 A Double-Blind Placebo-Controlled Pilot Trial of Varenicline (Chantix) for the Treatment of Cocaine Dependence Completed NCT00567008 Phase 2 varenicline;placebo
408 Cold Water Immersion Modulates Reinforcing Effects of Nitrous Oxide Completed NCT00000250 Phase 2 0% N2O;40% N2O
409 Prevention of Postrape Drug Abuse: Replication Study Completed NCT01430624 Phase 1, Phase 2
410 CS1008A Efficacy/Safety Trial of Buprenorphine/Naloxone Completed NCT00015028 Phase 2 Buprenorphine/naloxone
411 Dental and Medical Office Internet/Intranet Motivational Enhancement Therapy to Reduce Teen Tobacco, Alcohol, and Drug Use Completed NCT00907309 Phase 1, Phase 2
412 Effectiveness of Extended Treatment for Drug Dependence - City Supplement Completed NCT01153464 Phase 2
413 Behavioral Couples Therapy for Female Drug-Abusing Patients Completed NCT01189305 Phase 2
414 A Therapeutic Workplace for Alcohol Dependence Completed NCT00183144 Phase 2
415 Motivation and Skills for THC/ETOH+ Teens in Jail Completed NCT00227890 Phase 2
416 The Use of Acamprosate in Alcohol-Dependent Individuals With Bipolar Disorder Completed NCT00330486 Phase 1, Phase 2 Acamprosate
417 An Exploratory Study of Naltrexone Plus Aripiprazole for Alcohol Dependence Completed NCT00667875 Phase 2 Placebo;Naltrexone;Naltrexone + Aripiprazole
418 Yoga for Pain and Opioid Dependence Completed NCT01590251 Phase 1, Phase 2
419 Study of Routs of Naloxone Administration for Opioid Overdosed Patients Completed NCT01293058 Phase 2 Intranasal naloxone;Intravenous
420 Brief Intervention for Regular Prescription Drug Use and Prescription Drug Use Disorders in General Hospital Completed NCT00514839 Phase 2
421 New Approaches to Cocaine Abuse Medications (A) Completed NCT00000271 Phase 2 Desipramine;Placebo
422 Effects of Bupropion on Marijuana Withdrawal Symptoms Completed NCT00142870 Phase 2 Bupropion
423 D-Cycloserine and Cue Exposure in Cocaine-Dependent Individuals Completed NCT00780442 Phase 2 D-cycloserine;Placebo
424 Prescription Opioid Effects in Drug and Non-drug Abusers - 1 Completed NCT00158184 Phase 2 oxycodone 15 mg;oxycodone 30 mg;Placebo 0 mg
425 Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and Dependence Completed NCT02210195 Phase 2 aprepitant;Placebo
426 Prevention of Post-Rape Psychopathology and Drug Abuse Completed NCT01622855 Phase 1, Phase 2
427 AUDs and PTSD Treatment for Victims of Partner Violence Completed NCT00607412 Phase 2
428 A Multiple Dose Opioid Challenge Study to Assess Blockade of Subjective Opioid Effects of CAM2038 q1w (Buprenorphine FluidCrystal® Subcutaneous Injection Depots) In Adults With Opioid Use Disorder Completed NCT02611752 Phase 2 CAM2038
429 A Phase II, Double-blind, Placebo-Controlled, Pilot Trial of the Combination of Modafinil and Naltrexone for the Treatment of Cocaine and Alcohol Dependence Completed NCT00142818 Phase 2 Naltrexone;Modafinil;Placebo
430 Home-based Behavioral Therapy (HBT): Psychosocial Intervention Project for Early Adolescents With Pre- or Early Substance Use Disorder: Phase II Completed NCT00280228 Phase 2
431 D-Cycloserine Facilitation of Cocaine - Cue Extinction Completed NCT00759473 Phase 2 D-Cycloserine (DCS);Placebo
432 A Pilot RCT of Expressive Writing With HIV-Positive Methamphetamine Users Completed NCT01237366 Phase 1, Phase 2
433 Development of an Anxiety Sensitivity-Based Intervention for Substance Use and Anxiety Comorbidity Completed NCT02667015 Phase 2
434 Brain Function and Structure in Cocaine Dependence Completed NCT02080832 Phase 2 Citalopram;Placebo
435 MPD04961-Methylphendidate Treatment of Cocaine Dependent ADHD Patients Completed NCT00015054 Phase 2 Methylphenidate
436 Naltrexone Implants Compared to Methadone Maintenance Treatment (MMT) Among Inmates About to be Released From Prison - a Randomized Controlled Trial Completed NCT00204243 Phase 2 Naltrexone;Methadone
437 Maximizing the Patient-counselor Relationship to Reduce Sexual Risk Completed NCT03575585 Phase 2
438 Phase IIB Study of the Efficacy and Safety of LIBERTAL, A Phosphatidic-Acid-Enriched Phospholipid, on Smoking Cessation Completed NCT00317213 Phase 2 LIBERTAL- a phospholipid mixture
439 Dual Diagnosis Inpatients: Telephone Monitoring RCT to Improve Outcomes Completed NCT01135420 Phase 2
440 Gabapentin for Bipolar & Cannabis Use Disorders Completed NCT03334721 Phase 2 Gabapentin;Placebo Oral Capsule
441 Early Phase II Trials for Cocaine Medication Development Completed NCT00000317 Phase 2 Risperidone;Placebo
442 Combined Treatment for Alcohol-Dependent Individuals With PTSD Completed NCT00262223 Phase 2 Sertraline;Pill placebo
443 Place of Low-Dose Naltrexone in Opiate Detoxification Completed NCT00135759 Phase 2 Naltrexone;Placebo comparator;naltrexone;naltrexone
444 Pharmacogenetic Trial of Noradrenergic Medication for Treatment of Cocaine Abuse Completed NCT01953432 Phase 2 Doxazosin;Placebo
445 LAAM With Behavioral Treatment for Opioid/Cocaine Abuse Completed NCT00158288 Phase 2
446 Effectiveness of Disulfiram for Treating Cocaine Dependence in Individuals With Different Dopamine Beta Hydroxylase (DBH) Genes Completed NCT00149630 Phase 2 Disulfiram;Methadone
447 Career Training in Marijuana Dependence Completed NCT00149617 Phase 2 Buspirone
448 Increasing Treatment Adherence in Co-Occurring Disorders Completed NCT00237822 Phase 2
449 H-26605: Pharmacogenetics of Doxazosin for Cocaine Dependence Completed NCT01145183 Phase 2 Doxazosin;Placebo
450 Brief Intervention for Drug Abusing Students Completed NCT00350909 Phase 2
451 A Randomized, Single Center, Double-Blind, Multiple-Dose, Placebo-Controlled, Crossover, Double-Dummy Study of The Acute Behavioral and Subjective Effects of Ramelteon in Subjects With a History of Polydrug Abuse. Completed NCT00671632 Phase 2 Ramelteon, triazolam, and placebo (56 possible combinations total)
452 Interactive Voice Response Technology to Mobilize Contingency Management for Smoking Cessation Completed NCT01484717 Phase 2 transdermal nicotine
453 Experiment 1: Adenosine Receptor A2A Antagonists and Cocaine Dependence Completed NCT00733993 Phase 1, Phase 2 Caffeine 150 MG;Placebo;Amphetamine;Caffeine 300 MG
454 Development of a Methamphetamine Early Intervention Completed NCT01174654 Phase 1, Phase 2
455 Pilot Trial of a Therapeutic Interactive Voice Response System for Buprenorphine Maintenance: The Recovery Line Support System Completed NCT01315184 Phase 2
456 The Effects of Oxytocin on Couples Conflict Resolution Interactions Completed NCT02941692 Phase 2 Oxytocin;Placebo
457 Buprenorphine Effectiveness Evaluation in HIV Enhancement (BEEHIVE): A Randomized Trial of HIV Clinic-based Buprenorphine/Naloxone vs. Case Management and Referral in Opioid-dependent Individuals Completed NCT00130819 Phase 2
458 A Phase II, Randomized, Double-Blind Pilot Trial of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension) for the Treatment of Cocaine and Alcohol Dependence Completed NCT00777062 Phase 2 VIVITROL (Naltrexone extended-release injectable suspension);Placebo
459 New Medications to Treat Alcohol Dependence Completed NCT00223639 Phase 2 Topiramate
460 Glial Regulators for Treating Comorbid Posttraumatic Stress and Substance Abuse Disorders Completed NCT02499029 Phase 2 N-acetylcysteine;Placebo
461 Buprenorphine Maintenance for Opioid-Addicted Persons in Jail and Post-Release Completed NCT00367302 Phase 1, Phase 2 buprenorphine;methadone
462 Combined Treatment of Modafinil and Cognitive Behavioral Therapy for Cocaine Dependence Completed NCT00344565 Phase 2 Modafinil
463 The Efficacy of Mirtazapine in Depressed Cocaine Dependent Subjects Completed NCT00322309 Phase 2 Mirtazapine
464 Double Blind Placebo Controlled Study of PH94B for Management of the Symptoms of Generalized Social Phobia Completed NCT01217788 Phase 2 PH94B intranasal spray
465 A Phase 2, Double-Blind, Randomized, Placebo Controlled Trial to Assess the Efficacy of ABT-436 for Alcohol Dependence Completed NCT01613014 Phase 2 ABT-436;Matched Placebo - Sugar Pill
466 Cannabidiol as Treatment Intervention for Opioid Relapse Completed NCT01605539 Phase 2 Cannabidiol 400;Cannabidiol 800;Control
467 Behavior Change and Maintenance Intervention for HIV+ MSM Methamphetamine Users Completed NCT00432926 Phase 2
468 A Single-Center, Randomized, Double-Blind, Active- and Placebo-Controlled Crossover Study to Evaluate the Subjective Effects of PTI-801 in Non-Physically Dependent Subjects With a History of Drug Abuse Completed NCT00734461 Phase 2 oxycodone and naltrexone
469 Pharmacogenomics and Medication Development for Methamphetamine Dependence Completed NCT00833443 Phase 2 Bupropion
470 HIV Risk Reduction and Drug Abuse Treatment in Malaysia Completed NCT00383045 Phase 2 Buprenorphine/Subutex;Naltrexone
471 Targeted Social Network HIV Prevention Intervention Completed NCT00705705 Phase 2
472 Psychological First Aid for Victims of Crime Completed NCT01934348 Phase 1, Phase 2
473 Treatment of Anxiety and Anorexia Nervosa in Adolescents Completed NCT01933243 Phase 2 Fish oil;Placebo pill
474 Directly Observed Therapy for the Delivery of HCV Therapy Among HCV-infected Individuals in Chennai, India Completed NCT02541409 Phase 2 Sofosbuvir;Pegylated Interferon alfa-2a;Ribavirin
475 To Characterize the Acute and Short-term Effects of Cannabidiol (CBD) Administration on Cue-induced Craving in Drug-abstinent Heroin-dependent Humans Completed NCT02539823 Phase 2 CBD 400 mg;CBD 800 mg;Control (placebo)
476 HIV Risk Reduction Among Young Incarcerated Females Completed NCT00787696 Phase 1, Phase 2
477 PET Imaging of Dopamine D2 Receptors and Extracellular Dopamine With (18F)Fallypride, D-amphetamine, and Alpha-Methyl-Para-Tyrosine in Healthy Subjects Completed NCT00062946 Phase 2 (18F)fallypride
478 An Arts Intervention for Drug-Using Homeless Youth Completed NCT00862238 Phase 2
479 Concurrent Alcohol and Smoking Treatment: Effects on Alcohol Relapse Risk Completed NCT00861146 Phase 2
480 Recovery Management Checkups for Women Offenders Experiment Completed NCT01334164 Phase 2
481 Mindfulness Meditation For Alcohol Relapse Prevention Completed NCT01056484 Phase 2
482 Couples HIV Intervention Randomized Controlled Trial Completed NCT00325585 Phase 2
483 Behavioral Couples Group Therapy for Alcholic Patients: Clinical and Cost Outcomes Completed NCT01659957 Phase 2
484 Sertraline Augmented With GABA Agents for Cocaine Dependence Completed NCT00654953 Phase 2